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In recent years acquired azole resistance in Aspergillus 
fumigatus has been increasingly reported and a domi-
nant mechanism of resistance (TR34/L98H) was found 
in clinical and environmental isolates. The aim of the 
present study was to investigate the prevalence of 
azole resistance in environmental A. fumigatus iso-
lates collected in northern Italy. A. fumigatus grew 
from 29 of 47 soil samples analysed. Azole-resistant 
isolates were detected in 13% (6/47) of the soil sam-
ples and in 21% (6/29) of the soil samples containing 
A. fumigatus. High minimal inhibitory concentrations 
(MIC) of itraconazole (≥16 mg/L) and posaconazole 
(≥0.5 mg/L) were displayed by nine isolates from six 
different soil samples, namely apple orchard (1 sam-
ple), rose pot compost (2 samples), and cucurbit yields 
(3 samples). Seven isolates had a MIC=2 mg/L of vori-
conazole. Seven of nine itraconazole and posacona-
zole resistant isolates harboured the same TR34/L98H 
mutation of cyp51A. These findings, together with 
the occurrence of resistant clinical isolates, suggest 
that azole resistance should be considered in primary 
patient care.
Introduction
Aspergillus fumigatus is a filamentous fungus that 
causes a broad spectrum of diseases. Invasive life-
threatening infection affects subjects with com-
promised immune system, mainly patients with 
haematological malignancies, recipients of haemat-
opoietic stem cells or solid organ transplantation, or 
patients under prolonged treatment with steroids. 
Chronic aspergillosis occurs in patients with pre-exist-
ing pulmonary or sinus disease, and locally invasive 
infection occurs as a result of trauma or surgery.
A. fumigatus is ubiquitous in the soil and in decaying 
organic matter, and produces asexual spores (conidia) 
that are continuously dispersed in the air. Most of the 
patients develop aspergillosis following inhalation of 
conidia into the alveoli or the upper airways. Triazole 
antifungals, itraconazole, posaconazole and voricona-
zole, are increasingly used in the treatment and prophy-
laxis of aspergillosis [1]. Voriconazole is recommended 
as first line treatment for invasive aspergillosis in 
European and American guidelines [2-5].
A. fumigatus is generally susceptible to these antifun-
gals. However, in the recent years, azole resistance has 
been increasingly reported in patients under long-term 
antifungal treatment and also in azole naïve patients 
as well as in strains from the environment [1,6-8].
The most common mechanism of azole resistance is 
an alteration of lanosterol 14-α-demethylase, the key 
enzyme in the biosynthetic pathway of the ergosterol, 
a main component of the cell membrane. Different 
point mutations in the cyp51A gene, which encodes this 
enzyme, have been shown to confer resistance [1,9-11]. 
A dominant mechanism of resistance involving a 34-bp 
tandem repeat in the gene promoter region and a sub-
stitution of a leucine for a histidine at codon 98 (TR34/
L98H) was initially found in clinical and environmental 
isolates from the Netherlands and a correlation to the 
use of azoles in the environment was suggested [12].
During the international surveillance of azole resist-
ance in A. fumigatus clinical isolates (SCARE Network) 
intrinsic resistance was observed in four of 209 iso-
lates collected in Italy [13] and the TR34/L98H mutation 
was detected in all these isolates. The aim of the pre-
sent study was to investigate the prevalence of azole 
resistance in A. fumigatus environmental isolates col-
lected in northern Italy.
Methods
Environmental sampling was carried out in northern 
Italy in the period between May 2011 and June 2012. A 
total of 47 soil samples, namely 12 samples from apple 
orchard, 12 from cucurbit fields, six from vineyards, five 
from cereals fields, five from pot composts (including 
rose and other flower pot compost), three from flower-
beds of public gardens, three from hospital gardens, 
and one from compost purchased from a commercial 
garden centre, were examined. The sampling sites are 
reported in the map (Figure 1). Azole fungicides are 
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used in all the sampled environments, except gardens. 
No information was available for composts.
The samples were treated according to the method 
previously described by Snelders et al. [12] with minor 
modifications. Briefly, 2 g of each sample were sus-
pended in 8 mL of sterile distilled water added of 1% 
Tween 20 (Sigma, St. Louis USA) and chloramphenicol 
(0.5 g/L, Sigma) and vortexed. The suspension was 
stored at room temperature for 30 to 60 min and 100 
µL of the supernatant was inoculated on two plates of 
Sabouraud dextrose agar (SDA, Biolife, Milan, Italy) 
supplemented with chloramphenicol (0.5 g/L) and on 
two plates of SDA supplemented with chloramphenicol 
and itraconazole (4 mg/L, Janssen, Beerse, Belgium). 
Control plates and itraconazole-containing plates 
were incubated at 37° C and at 42° C (to limit the fun-
gal growth) and examined after 24, 48, and 72 hours 
of incubation. All the A. fumigatus isolates grown on 
itraconazole-containing agar and an equal number of 
isolates grown on control plates were selected and 
maintained on SDA medium.
The isolates were identified by macroscopic and micro-
scopic morphology on Czapek agar medium (Difco, 
Becton Dickinson, Buccinasco, Italy) as A. fumigatus 
species complex.
A. fumigatus isolates grown in presence of itracona-
zole and an equal number of isolates grown on con-
trol plates were tested for antifungal susceptibility 
to itraconazole, posaconazole and voriconazole. 
Susceptibility testing was performed, within one month 
from the isolation, by broth microdilution method 
according to European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) methodology [14]. The 
minimal inhibitory concentration (MIC) of all the azoles 
was determined visually as the lowest concentration of 
drug giving a complete inhibition of fungal growth. All 
tests were performed in duplicate. Candida parapsilo-
sis ATCC 22019 and C. krusei ATCC 6258 were included 
as quality control in each test. 
Susceptibility testing was also performed using Etest 
strips (BioMérieux, Bagno a Ripoli, Italy) on RPMI 1640 
agar supplemented with 2% glucose, according to the 
manufactory indications. Isolates with MIC of itracona-
zole and voriconazole >2mg/L and those with MIC of 
posaconazole >0.25mg/L were considered resistant, 
according to the EUCAST breakpoints [15-17]. 
Genomic DNA was extracted from the nine azole-resist-
ant and four susceptible isolates using the PrepMan 
Ultra sample preparation reagent (Applied Biosystems, 
Foster City, CA). Identification of the isolates as A. 
fumigatus in sensu stricto was confirmed by the ampli-
fication and sequencing of a portion of the beta-tubulin 
Figure 1
Map of northern Italy reporting the sampling sites for Aspergillus fumigatus, May 2011—June 2012
Only sites where more than one sample could be analysed, are shown.












Compost from garden centre
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gene using the primers described elsewhere [9]. The 
sequences obtained were compared to the sequences 
present in the GenBank database (www.ncbi.nlm.
nih.gov) by basic local alignment search tool (BLAST) 
analysis and the identification was confirmed if a 99 to 
100% sequence identity was observed.
In addition, two further DNA regions, one inside 
the cyp51A gene and one inside its promoter, were 
sequenced to detect the presence of the point muta-
tion t364a , which leads to the L98H substitution at 
the protein level, and the 34-bp tandem repeat, both 
specific for azole resistance. The cyp51A gene frag-
ment (1168 bp) was amplified by polymerase chain 
reaction (PCR) using the two primers, P450-A1 [11] and 
Cyp51AR2 (5’-AGTGAATAGAGGAGTGAATCC-3’). PCR was 
performed in a 50-mL volume containing 10X buffer 
(10 mM Tris-HCL, pH 8.3; 500 mM KCl; 15 mM MgCl2; 
Qiagen, Venlo, Netherlands), 1.5 mM MgCl2, 200 mM 
of each of the four deoxynucleotides, 20 pmol of each 
primer, 2.5 U of Taq polymerase (Qiagen), and 2 mL 
of genomic DNA. The thermal cycling profile included 
an initial step at 94°C for 5 min, 30 cycles consisting 
in denaturation at 94°C for 30 s, annealing at 58°C 
for 30 s, and extension at 72°C for 1 min, and a final 
extension at 72°C for 5 min. The PCR product was 
then sequenced using two forward primers, P450-A1 
and Cyp51AF2 (5’-GACATCTCTGCGGCAATGG-3’), 
and two reverse primers, Cyp51AR2 and Cyp51AR3 
(5’-CCATTGCCGCAGAGATGTC-3’), to reach the complete 
sequencing coverage for both strands of the frag-
ment. The cyp51A gene promoter was amplified and 
sequenced using the primers PA5 and PA7 as previ-
ously described [10].
All sequences were determined by an ABI PRISM 3100 
genetic analyser (Applied Biosystems), electrophero-
grams were analysed by FinchTV software (www.geo-
spiza.com), and sequence alignment was performed 
using ClustalW algorithm (www.ebi.ac.uk). The cyp51A 
sequence from A. fumigatus strain 237 (GenBank 
accession number: AF338659) was used as wild type 
reference.
Azole-resistant as well as five susceptible isolates were 
genotyped by microsatellite analysis using the primers 
STRAf3A, STRAf3B, STRAf3C, STRAf4A, STRAf4B, and 
STRAf4C as described elsewhere [18].
Results
A. fumigatus grew in 29 of 47 soil samples (62%), 
mainly form cucurbit and cereal fields and rose pot 
composts (Table 1). No A. fumigatus was isolated from 
vineyards and compost from garden centre. A total of 
58 isolates grew on itraconazole-containing agar. 
Broth microdilution and Etest confirmed itraconazole 
resistance in nine isolates (MIC ≥16 mg/L). All these 
isolates were also posaconazole resistant (MIC ≥0.5 
mg/L). Seven isolates showed an intermediate suscep-
tibility to voriconazole (MIC =2 mg/L) by broth microdi-
lution method according to EUCAST (Table 2). Etest MIC 
values were lower but MIC values obtained by broth 
microdilution and Etest were in the +/- 2 dilution range. 
The A. fumigatus control isolates were susceptible to 
itraconazole (range of MICs: 0.06 to 0.12 mg/L), posa-
conazole (range of MICs: ≤0.03 to 0.06 mg/L), and vori-
conazole (range of MICs: 0.06 to 0.25 mg/L). Identical 
results were obtained in tests performed in duplicate.
Table 1
Environmental origin of itraconazole-resistant Aspergillus fumigatus isolates, Italy, May 2011–June 2012
Sample source Period of sampling Examined samples (n)
Samples with 


















Apple orchard Oct–Dec 2011 12 3 1 1 1a
Cereal fields Mar–Apr 2012 5 5 0 0 0
Compost from garden centre Apr 2012 1 0 0 0 0
Cucurbit fields May and Sep 2011 12 10 8 28 6b
Hospital gardens Mar–Jun 2012 3 3 0 0 0
Pot compost May 2011 5 5 2 29 2c
Public gardens Apr–May 2012 3 3 0 0 0
Vineyards Oct 2011 6 0 0 0 0
Total – 47 29 11 58 9
a The isolate corresponds to one sample collected in the Lombardy region near the northern Italian border.
b The isolates were derived from three samples respectively collected in different fields and/or dates near the city of Milan.
c The isolates were derived from two samples from two different rose pots collected near the city of Genoa.
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Table 2
Results of EUCAST and Etest susceptibility testing, and analysis of mutations in cyp51A, Italy, May 2011–June 2012 
Isolate 
number Sample source
MIC (mg/L) determined by EUCAST MIC (mg/L) determined by Etest
Mutation in cyp51A
ITZa POSa VRCa ITZa POSa VRCa
11-0087A Rose pot compost >16 1 2 >32 1 1 TR34/L98H
11-0088E Rose pot compost >16 2 1 16 0.5 1 None
11-0099A Cucurbit fields >16 2 2 >32 1 2 TR34/L98H
11-0104A Cucurbit fields >16 1 2 >32 0.5 2 TR34/L98H
11-0104B Cucurbit fields >16 1 2 >32 0.5 2 F46Y; M172V; N248T; D255E
11-0104D Cucurbit fields >16 1 2 >32 1 1 TR34/L98H
11-0317C Cucurbit fields >16 2 2 >32 0.5 0.5 TR34/L98H
11-0317D Cucurbit fields >16 1 1 >32 0.5 1 TR34/L98H
11-0396 Apple orchard >16 2 2 >32 0.5 1 TR34/L98H
EUCAST: European Committee on Antimicrobial Susceptibility Testing; MIC: minimal inhibitory concentration.
Isolates with MIC of itraconazole and voriconazole >2mg/L and those with MIC of posaconazole >0.25mg/L by broth microdilution method 
according to EUCAST, were considered resistant [15-17]. Data obtained by EUCAST and Etest differed, however results in a +/- 2 dilution 
range are considered acceptable.
a The azoles used for susceptibility testing were ITZ (itraconazole), POS (posaconazole), VRC (voriconazole).
Figure 2
Alignment of three amino acid sequences derived from the Cyp51A genetic sequence from itraconazole susceptible and 
resistant isolates, Italy, May 2011–June 2012
An asterisk (*) indicates that the amino acid in the sequence is identical to that of the sequence presented at the top of the alignment. 
The sequence 11-0087C is derived from an itraconazole susceptible (S) isolate, while the sequences 11-0099A, with the resulting L98H 
mutation, and 11-0104B, with other resulting amino acid substitutions, are from respective itraconazole resistant (R) isolates.
11-0087C (S) MVPMLWLTAYMAVAVLTAILLNVVYQLFFRLWNRTEPPMVFHWVPFLGSTISYGIDPYKF 60
11-0099A (R) ************************************************************ 60
11-0104B (R) *********************************************Y************** 60
11-0087C (S) FFACREKYGDIFTFILLGQKTTVYLGVQGNEFILNGKLKDVNAEEVYSPLTTPVFGSDVV 120
11-0099A (R) *************************************H********************** 120
11-0104B (R) ************************************************************ 120
11-0087C (S) YDCPNSKLMEQKKFIKYGLTQSALESHVPLIEKEVLDYLRDSPNFQGSSGRMDISAAMAE 180
11-0099A (R) ************************************************************ 180
11-0104B (R) ***************************************************V******** 180
11-0087C (S) ITIFTAARALQGQEVRSKLTAEFADLYHDLDKGFTPINFMLPWAPLPHNKKRDAAHARMR 240
11-0099A (R) ************************************************************ 240
11-0104B (R) ************************************************************ 240
11-0087C (S) SIYVDIINQRRLDGDKDSQKSDMIWNLMNCTYKNGQQVPDKEIAHMMITLLMAGQHSSSS 300
11-0099A (R) ************************************************************ 300
11-0104B (R) *******T******E********************************************* 300
11-0087C (S) ISAWIMLRLASQPKVLEELYQEQLANLGPAGPDGSLPPLQYKDLDKLPFHQHVIRETLRI 360
11-0099A (R) ************************************************************ 360
11-0104B (R) ************************************************************ 360
11-0087C (S) HSSIH 365
11-0099A (R) ***** 365
11-0104B (R) ***** 365
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The nine itraconazole- and posaconazole-resistant 
isolates were recovered from pot composts (2 iso-
lates from 2 different rose pots from Genoa), from 
apple orchard (1 isolate from an apple orchard near the 
northern border of Italy), and from cucurbit fields (6 
isolates). These last six isolates were from three differ-
ent samples, 11-0099, 11-0104 and 11-0317, collected in 
different fields and/or dates.
All nine resistant isolates were identified as A. fumiga-
tus sensu stricto by amplification of a fraction of the 
beta-tubulin gene.
Sequence analysis of cyp51A gene showed the t364a 
point mutation, which results in the L98H substitu-
tion, combined with the 34-bp tandem repeat in the 
promoter region, in seven of nine itraconazole- and 
posaconazole-resistant isolates (Table 2). The TR34/
L98H alteration was neither detected in the four azole 
susceptible isolates used as control nor in the resist-
ant isolates 11-0088E and 11-0104B. No mutation in the 
cyp51A gene was found in the recovered sequence of 
11-0088E. The other resistant isolate (11-0104B) lack-
ing the mutation leading to the L98H substitution had 
four other inferred amino acid changes at codons 46, 
172, 248 and 255, as reported in Figure 2.
Eight of nine resistant isolates (one was no more vital) 
and five additional susceptible environmental isolates 
were genotyped by microsatellite analysis. The results 
showed that all the isolates presented genotypes dif-
ferent from each other (Table 3).
Discussion
Acquired resistance to azoles develops in response to 
exposure of fungi to azole compounds in patients and 
in agricultural settings and is favoured by long duration 
of exposure to these compounds and high numbers of 
reproducing fungi [1,19,20]. Acquisition of resistance 
in patients is characterised by a variety of resistance 
mechanisms. The dominance of the TR34/L98H resist-
ance mechanism in unrelated clinical isolates in a large 
Dutch culture collection suggested that isolates with 
this mechanism might be present in the environment, 
favoured by azole fungicides used in agriculture [20]. 
The detection of the TR34/L98H resistance mechanism 
also in Italy, in four A. fumigatus isolates from two 
azole-naïve patients among the 209 isolates tested in 
the SCARE project [13] and in an additional isolate from 
an azole-exposed patient, lead to investigate the pres-
ence of azole-resistant A. fumigatus in the environment 
in our country.
Nine of the 58 isolates obtained by screening soil 
samples collected in northern Italy on an itraconazole 
containing medium were confirmed to be resistant to 
itraconazole and posaconazole by MIC determined 
with broth microdilution and Etest. Seven of these 
nine had also a reduced susceptibility to voriconazole 
when tested with broth microdilution. The discrepancy 
between the numbers of isolates on the screening 
medium containing itraconazole at a concentration of 4 
mg/L and the numbers of confirmed resistant isolates 
could be attributed to trailing of organic compounds 
present in the soil.
Table 3
Allelic profiles at six microsatellite loci of itraconazole resistant (n= 8) and susceptible (n=5) environmental isolates, Italy, 
May 2011–June 2012
Isolate R/S
Fragment size as bp (number of repeats)
STRAf3A STRAf3B STRAf3C STRAf4A STRAf4B STRAf4C
11-0087A R 292 (60) 164 (10) 78 (5) 182 (9) 185 (9) 185 (10)
11-0088E R 190 (27) 169 (12) 80 (6) 231 (20) 184 (9) 175 (7)
11-0099A R 310 (66) 158 (8) 78 (5) 179 (8) 185 (9) 185 (10)
11-0104A R 323 (70) 158 (8) 86 (8) 179 (8) 185 (9) 175 (7)
11-0104B R 161 (18) 162 (9) 108 (15) 201 (13) 184 (9) 175 (7)
11-0104D R 179 (23) 160 (9) 78 (5) 183 (9) 184 (9) 185 (10)
11-0317C R 203 (31) 164 (10) 75 (4) 186 (10) 180 (8) 224 (20)
11-0396 R 310 (66) 158 (8) 80 (6) 178 (8) 184 (9) 185 (10)
11-0023B S 212 (34) 164 (10) 194 (42) 196 (12) 184 (9) 175 (7)
11-0034A S 212 (34) 156 (7) 80 (6) 182 (9) 180 (8) 242 (26)
11-0036C S 222 (37) 164 (10) 80 (6) 196 (12) 175 (7) 162 (5)
11-0087C S 190 (27) 162 (9) 118 (18) 182 (9) 196 (12) 162 (5)
11-0104E S 219 (36) 169 (12) 80 (6) 185 (10) 192 (11) 181 (9)
R: itraconazole resistant; S: itraconazole susceptible.
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Azole-resistant A. fumigatus sensu stricto were 
detected in 13% (6/47) of the soil samples collected and 
in 21% (6/29) of the soil samples confirmed as contain-
ing A. fumigatus. These results are in agreement with 
the data from other European countries: resistant iso-
lates were detected in 8% of soil samples and in 11% 
of samples containing A. fumigatus in Denmark [8] and 
in 20.4% of A. fumigatus positive soil samples in the 
Netherlands [12]. Due to the limited number of samples 
it was impossibile to note a seasonal variation 
Molecular analysis showed the presence of the TR34/
L98H resistance mechanism in seven of nine resist-
ant isolates. This resistance mechanism has also been 
reported in clinical isolates from several European and 
Asian countries [1,7,9,13,21-25]. To explain the preva-
lence of this resistance mechanism it was hypothe-
sised that TR34/L98H isolates may have an advantage 
with respect to fitness compared to isolates with other 
mutations [6]. Other point mutations (in codons 46, 
172, 248, 255) were detected in one of the remaining 
resistant isolate. These mutations have been reported 
by other authors, and were found in both azole-sus-
ceptible and resistant strains [7,26,27]. No mutation 
was observed in the sequenced cyp51A gene of the 
other resistant isolate. These two resistant isolates 
would suggest the existence of other mechanisms of 
resistance.
As shown by molecular typing, all the resistant isolates 
were characterised as different strains confirming 
that resistance does not arise by a clonal expansion 
of a mutant but it is likely induced by the selective 
pressure resulting from the presence of azoles in the 
environment.
In conclusion this study provides evidence that azole-
resistant A. fumigatus are detected in the environment 
also in Italy, in soil or composts exposed to azole fun-
gicides, and confirms the presence of the TR34/L98H 
mutation in several countries in Europe. Susceptibility 
testing of filamentous fungi is not routinely carried out 
in most medical microbiology laboratories, however 
the risk for patients to acquire multi-azole-resistant 
strains from the environment could have a serious 
impact on the management of life-threatening invasive 
infections. Finally, the possible selection of resistant 
fungal pathogens should lead applying azoles in agri-
culture with caution.
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